Frank Chen
Chairman of the Board
Mr. Chen is currently serving as Vice General Manager, Investment Management and Special Assistant to Chairman of Ruentex Group.
He obtained his Master’s degree in Business Administration from National Taiwan University.
Jeng Her
Director
Dr. Jeng Her is the founder and CEO of AP Biosciences. He had received a bachelor’s degree in Physics from the National Taiwan University, then turned into biology and earned a Ph.D. degree in Microbiology and Immunology from the University of Virginia in 1993.
Before setting up AP Biosciences in Taiwan, he had co-founded KaloBios Pharmaceuticals in the Silicon Valley soon after his post-doctoral training at Bristol-Myers Squibb and DNAX Research Institute (now part of Merck). At KaloBios, he co-invented the antibody Humaneering™, a technology which converts non-human antibodies into engineered human-like antibodies with sequences close to the germline to minimize immunogenicity. The technology was then licensed to Novartis non-exclusively for $32M. In 2013, KaloBios went public on NASDAQ with three antibodies in clinical trials, including KB001 for ventilator-associated pneumonia, which was licensed to Sanofi-Pasteur for $270 million.
Audrey Tseng
Director
Ms. Audrey is Honorary Deputy Chairman of PwC Taiwan, Adjunct Professor of National Chengchi University, Advisor of BioTReC of Academia Sinica and Advisor of Ministry of Health and Welfare.
Ms. Audrey holds a Master of Business Administration, Executive MBA Program of Fudan University and National Taiwan University, and a Master of Commerce, Department of Accounting, National Chengchi University.
With over 35 years of experience as a Taiwan-licensed CPA, she has successfully assisted many biopharma and medtech companies to list in Taiwan. Audrey also has extensive overseas IPO advisory experiences.
Ming-Tain Lai
Director
Dr. Lai has more than 23 years of experience in drug discovery. As Senior Principal Scientist at Merck & Co., Dr. Lai led and directed multiple independent project teams to develop potential clinical candidates. He also acted as a core team member of early development and product development in several clinical studies.
During his tenure at Merck, the teams have identified more than 10 preclinical candidates. Several of them are currently in clinical trials. He also received several awards from Merck, Merck Divisional/Staff Area Award in 2007, Special achievement award in 2009, and Merck Research Laboratories Pipeline Award in 2018. The crowning achievements of his career at Merck comes with the approval of an antiviral drug by FDA in 2018.
Dr. Lai has had over 69 papers published in peer-reviewed journals. Dr. Lai did post-doctoral study in at Massachusetts Institute of Technology, earned his Ph.D. in Bio-Organic Chemistry from University of Minnesota.
Su-Ming Lin
Independent Director
Ph.D., Arizona State University (Accounting)
Associate Dean, College of Management, NT
Independent Director of Chunghwa Telecom Co., Ltd.
Independent Director of Taiwan Fertilizer Co., Ltd.
Commissioner of the Appeals Review Committee, Taipei City Government
Commissioner of the Reformation of Taxation Committee, Executive Yuan
Consultant of Certified Public Accountant, ROC
Andrew H. -J. Wang
Independent Director
Ph.D., Chemistry, University of Illinois-Urbana
Vice President, Academia Sinica
Director of the Hsing Tian Kong Foundation Medical Misson
Director of Taiwan Medical University
Independent Director of Standard Chem & Pharm Co., Ltd.
Tsong-Juh Chiu
Independent Director
National JD, National Taiwan University
Chairman of Securities & Futures Institute
Chair Professor of Fu Jen Catholic University
Peace & Grace International Attorney at Law
Independent Director of Sinew Pharma Inc.
Independent Director of Ever Ohms Technology Co., Ltd.
